Premium
Spironolactone. III. Canrenone—maximum and minimum steady‐state plasma levels
Author(s) -
Karim A.,
Zagarella J.,
Hutsell T. C.,
Dooley M.
Publication year - 1976
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1976192177
Subject(s) - spironolactone , steady state (chemistry) , plasma concentration , medicine , half life , zoology , endocrinology , pharmacology , chemistry , pharmacokinetics , heart failure , biology
Steady‐state plasma levels of canrenone have been examined in 23 healthy men who received repeated doses of spironolactone for 15 days. The dose regimens were 200 mg once a day and 50 mg 4 times a day. With both treatments the steady‐state levels were reached after 3 to 4 days. With once‐a‐day treatment, the maximum and minimum steady‐state levels were about 500 and 100 nglml, respectively. The minimum levels with treatment 4 times a day were about 200 ng/ml. The post steady‐state half‐life of canrenone with once‐a‐day treatment (19.2 ± 6.57 hr) was longer (p < 0.01) than the half‐life obtained in the 4‐times‐a‐day treatment (12.5 ± 3.39 hr). The former half‐life was similar to the log‐linear phase half‐life of canrenone in the single‐dose studies.